Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 342

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation

Open access
Garcia-Borreguero, Diego, Silber, Michael H., Winkelman, John W., Högl, Birgit, Bainbridge, Jacquelyn, Buchfuhrer, Mark, Hadjigeorgiou, Georgios, Inoue, Yuichi, Manconi, Mauro, Oertel, Wolfgang, Ondo, William, Winkelmann, Juliane, Allen, Richard P.·2016·Sleep Medicine

Abstract

A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if dopaminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appropriate iron supplementation. Daily treatment by either medication should start only when symptoms have a significant impact on quality of life in terms of frequency and severity; intermittent treatment might be considered in intermediate cases. Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or increasing the dose if there are breakthrough night-time symptoms. Alternatively, the patient can be switched to an α2δ ligand or rotigotine. For severe augmentation the patient can be switched either to an α2δ ligand or rotigotine, noting that rotigotine may also produce augmentation at higher doses with long-term use. In more severe cases of augmentation an opioid may be considered, bypassing α2δ ligands and rotigotine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.sleep.2016.01.017

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 7

  1. Mitterling, 2014, Is there a polysomnographic signature of augmentation in restless legs syndrome?, Sleep Med, 15, 1231, 10.1016/j.sleep.2014.05.023 · doi:10.1016/j.sleep.2014.05.023
  2. Garcia-Borreguero, 2008, Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials, Eur J Neurol, 15, 110
  3. Benes, 2009, Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine – a retrospective systematic analysis of two large open-label 1-year trials, Mov Disord, 24, S438
  4. Garcia-Borreguero, 2012, Long-term efficacy and augmentation assessment of a dopamine agonist (pramipexole) compared with an alpha-2-delta ligand (pregabalin) in restless legs syndrome: results of a randomized, double-blinded, placebo-controlled trial, Neurology, 78, P01.
  5. Godau, 2011, Rotigotine in the long-term treatment of severe RLS with Augmentation: a series of 28 cases, Sleep Disord, 2011, 468952, 10.1155/2011/468952 · doi:10.1155/2011/468952
  6. Miranda, 2013, [Transdermal Rotigotine in the treatment of restless legs patients who develop augmentation of symptoms], Rev Med Chil, 141, 407
  7. Kurlan, 2013, Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy, J Park RLS, 3

Cited by

See all 342

Metadata

Authors
Garcia-Borreguero, D., Silber, M. H., Winkelman, J. W., Högl, B., Bainbridge, J., Buchfuhrer, M., Hadjigeorgiou, G., Inoue, Y., Manconi, M., Oertel, W., Ondo, W., Winkelmann, J., & Allen, R. P.
Venue
Sleep Medicine
Publisher
Elsevier BV
Published
2016-05
Volume
21
Pages
1-11
ISSN
1389-9457 (ISSN-L)
OpenAlex
W2337607729
Cited by
342
References
45
FWCI
29.98
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. https://app.cochat.ai/papers/10.1016/j.sleep.2016.01.017
The paper
Garcia-Borreguero, D., Silber, M. H., Winkelman, J. W., Högl, B., Bainbridge, J., Buchfuhrer, M., Hadjigeorgiou, G., Inoue, Y., Manconi, M., Oertel, W., Ondo, W., Winkelmann, J., & Allen, R. P. (2016). Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine. https://doi.org/10.1016/j.sleep.2016.01.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.